Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Share-based Compensation: 2020-2025

Historic Share-based Compensation for 4D Molecular Therapeutics (FDMT) over the last 6 years, with Sep 2025 value amounting to $4.5 million.

  • 4D Molecular Therapeutics' Share-based Compensation fell 30.37% to $4.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $24.0 million, marking a year-over-year decrease of 1.67%. This contributed to the annual value of $26.1 million for FY2024, which is 32.80% up from last year.
  • Per 4D Molecular Therapeutics' latest filing, its Share-based Compensation stood at $4.5 million for Q3 2025, which was down 8.85% from $5.0 million recorded in Q2 2025.
  • In the past 5 years, 4D Molecular Therapeutics' Share-based Compensation ranged from a high of $7.6 million in Q4 2024 and a low of $2.3 million during Q1 2021.
  • Moreover, its 3-year median value for Share-based Compensation was $5.9 million (2023), whereas its average is $5.7 million.
  • Per our database at Business Quant, 4D Molecular Therapeutics' Share-based Compensation surged by 267.98% in 2021 and then tumbled by 30.37% in 2025.
  • 4D Molecular Therapeutics' Share-based Compensation (Quarterly) stood at $3.7 million in 2021, then rose by 16.48% to $4.3 million in 2022, then skyrocketed by 36.06% to $5.9 million in 2023, then rose by 28.16% to $7.6 million in 2024, then crashed by 30.37% to $4.5 million in 2025.
  • Its Share-based Compensation stands at $4.5 million for Q3 2025, versus $5.0 million for Q2 2025 and $7.0 million for Q1 2025.